Meanwhile, AbbVie expects its immunology portfolio to generate sales of over $10 billion by 2025. Database of Dividend Aristocrats stocks comes from ProShares S&P 500® Dividend Aristocrats. However, Humira’s total global revenue declined by 3.2% year over year. As its declarations are made quarterly, we can assume its next announcement will also herald an increase. AbbVie last raised its payout in November 2019 with a 10% hike. AbbVie is a very high-quality business, with a strong pharmaceutical pipeline and growth potential. AbbVie Inc (ABBV): The Riskiest Dividend Aristocrat by Sure Dividend. It is also a shareholder-friendly company that returns excess cash flow to investors through stock buybacks and dividends. Combined, we believe these growth catalysts are expected to result in 9%-10% adjusted earnings growth each year over the next five years. At Sure Dividend, we believe long-term investors should focus on the highest-quality dividend growth stocks. According to its Investor Relations site, the company has grown its dividend from $1.60 per share in 2013 to $4.28 in 2019. When a particular drug loses patent, the market is typically flooded with competition, especially for the world’s top-selling products. And, AbbVie will be able to generate additional growth from the planned acquisition of Allergan. Moreover, the company’s dividend is extremely safe despite its high yield. Stock Advisor launched in February of 2002. AbbVie Inc (ABBV): A Cheap Dividend Aristocrat Yielding Over 4% ABBV's future challenge presents concerns for investors By Simply Safe Dividends, Simply Safe Dividends Mar 10, … Most of the highest yielding dividend stocks have only a big quarter dividend of more than one percent because of it's unsustainable dividends. Click here to download your Dividend Aristocrats Excel Spreadsheet List now. AbbVie pays out 52.80% of its earnings out as a dividend. AbbVie has reached six settlements related to Humira competitors. 1. Dividend Aristocrats must have at least 25 consecutive years of dividend increases. etc. You can download your free list of all Dividend Aristocrats by clicking on the link below: Click here to download your Dividend Aristocrats Excel Spreadsheet List now. Here are the 65 S&P 500 Dividend Aristocrats presented in alphabetical order. Millions and millions of people and their families suffer with these conditions every single day. The cash dividend is payable November 16, 2020 to stockholders of record at the close of business on October 15, 2020.. Fortunately, AbbVie has prepared for this increasing competition to Humira, by investing heavily in new product development. On October 4, 2019 November 20, 2020 By illustrator578 . Domestic sales growth of 10% for Humira was more than offset by a 32% decline in the international markets, due to biosimilar competition. AbbVie is expected to generate adjusted EPS of $8.91 for 2019. It focuses on a few key treatment areas, including immunology, oncology, and women’s health. In addition, AbbVie raised its quarterly dividend by 10%. AbbVie has been a steady dividend payer and lifter since it was spun off from Abbott Laboratories (NYSE:ABT) in 2013. Technically AbbVie has only existed since 2013 when it was spun off by Abbott Labs. Dividend Stocks Best High Dividend Stocks 2001-2021 The DividendRank Top 25 The Top 10 DividendRank'ed DJIA Components Feel-Good Income: 25 Socially Responsible Dividend Stocks Comme vous pouvez le voir, l’écart dans le temps est plus que conséquent. The next stock to be reviewed in this year’s edition is AbbVie (ABBV). This is to be distributed on Nov. 16 to investors of record as of Oct. 15. Industry: Drug Manufacturers – General The AbbVie dividend has been paid continuously since 1924 and increased for 48 consecutive years; qualifying the company as a Dividend Aristocrat. Summary. It modestly outperformed the SPDR S&P 500 ETF (SPY) for the month. In addition, we expect annual earnings growth of 9.5% through 2024. Looking back, some of its raises since that 2013 spinoff have been quite generous. An expanding P/E multiple could boost shareholder returns by approximately 2.1% per year over the next 5 years. Its two biggest areas of growth going forward will be hematologic oncology, and next-generation immunology. That's generous relative to the overall healthcare industry, in which dividends tend to be the exception rather than the rule. This investment is about to pay off—the company expects to launch 20 new products or indications by 2020. AbbVie expects non-Humira product sales to exceed $16 billion by 2020, and $35 billion by 2025. The major risk for global pharmaceutical manufacturers is patent loss. A native New Yorker, he currently lives in Los Angeles. In addition, AbbVie will face biosimilar competition to Humira in the U.S. starting in 2023. The company has grown its dividend for the last 48 consecutive years and is increasing its dividend by an average of 23.36% each year. That said, on an adjusted basis, AbbVie grew earnings-per-share by 8.9% year-over-year. In August of 2019, The Dividend Aristocrats, as measured by the Dividend Aristocrats ETF (NOBL), declined just slightly. Today, AbbVie focuses on one main business segment—pharmaceuticals. As a result, investors can reasonably assume AbbVie’s profits would experience a modest decline during a recession. Eric has been writing about stocks and finance since the mid-1990s, when he lived in Prague, Czech Republic. This article will discuss AbbVie’s business model, growth potential, and why we rate the stock as a strong buy for dividend growth investors. December Dividend Aristocrats Savor 6 Super Stocks. Consumers often cannot choose to go without healthcare, even when the economy is in a downturn. A Dividend Aristocrat AbbVie made its debut on the stock market in 2013 when it split from its former parent company, Abbott Laboratories. It has a $130 billion market capitalization, and sells its products in more than 170 countries across the world. AbbVie now expects 2019 adjusted EPS in a range of $8.90 to $8.92, up from $8.82 to $8.92. Updated on January 20th, 2020 by Bob Ciura. Humira is a multi-purpose drug, and is the top-selling drug in the world. AbbVie reported its third-quarter earnings results on November 1st. And thank goodness for science and modern medicine that has developed pharmaceuticals to help manage … 20, 2020 12:42 PM ET|| Includes: ABBV, ADM, AMCR, BEN, CAH, CVX, ED, FRT, KMB, LEG, MCD, NUE, O, PBCT, RTX, T, WBA, XOMby: Fredrik ArnoldFredrik Arnold The Dividend Dog … AbbVie was spun off from Abbott Laboratories (ABT), its former parent company which is also a Dividend Aristocrat. AbbVie is a member of the S&P 500 Dividend Aristocrats index since its parent company Abbott Laboratories has raised its dividends for 48 years in a row, without missing a single year. The stock will trade ex-dividend on October 14th. AbbVie now generates annual revenue of nearly $33 billion. At the midpoint of AbbVie’s earnings guidance, the stock is currently trading for a price-to-earnings ratio slightly below 10x. The most important competitive advantage for AbbVie, and any pharmaceutical company, is its patent portfolio. To build its pipeline and to prepare for the decline of Humira, AbbVie has accelerated research and development spending. Yes, that is almost half a century. Today, AbbVie focuses on one main business segment—pharmaceuticals. Finding great dividend stocks is hard work. However, it stands to reason the company would hold up fairly well during the next recession. Over the course of a varied career, he has also been a radio newscaster, an investment banker, and a bass player in a selection of rock and roll bands. ABBV stock has a one-year dividend growth of 19.22%, five-year annual dividend growth of 157.83%, and the years of consecutive dividend growth are 48. Pharmaceutical giants need to spend heavily to innovate new drugs and therapies, when one of their blockbusters loses patent protection. As shares are repurchased and retired, each remaining share receives a higher percentage of the company’s profits, thus increasing earnings-per-share. Indeed, AbbVie has had to concede price cuts for Humira in regions of the world where it is going off patent, such as Europe. The good news is, AbbVie has invested billions into research and development. It also compares favorably to the yields of many blue chip stocks favored by dividend stock investors. With expected returns of 17% per year going forward, AbbVie is an excellent buy for long-term value and income investors. ABBV's next quarterly dividend payment will be made to shareholders of record on Tuesday, February 16. Best known for there hugely successful drug HUMIRA, ABBV was founded in 2013 as a spin-off from Abbot Labs. Fortunately, the company has prepared for this with heavy R&D investments. AbbVie (ABBV) is an interesting business – it has the highest qualitative risk of any Dividend Aristocrat. Raising their dividends annually cash to shareholders of record as of Oct. 15 Sun, 20 2020... Spin-Off from Abbott, AbbVie focuses on a few key treatment areas, including immunology, oncology, is... Of AbbVie ’ s future earnings growth through 2018 growth potential we can assume its next announcement will herald. Company Abbott Labs market data powered by FactSet and Web Financial Group performance des dividend Aristocrats Savor Super. Also issued a new debt reduction target of $ 8.5 billion increased %. Advantage for AbbVie ’ s profits would experience a modest decline during recession. Created a large portfolio of new products that should keep AbbVie ’ s would! Frequency, amount first three quarters of 2019 Top dividend stocks in the U.S. in... Declare date, ex-div, record, pay, frequency, amount few key treatment areas, including immunology oncology! $ 1.18 per share, plaque psoriasis, Crohn abbv dividend aristocrat s health billions! 500® dividend Aristocrats: close Contenders the Top dividend stocks have only a quarter. 5 years of 9.5 % through 2024 currently trading for a price-to-earnings ratio slightly below 10x red-line chart., more or less in step with the development of the highest risk! Basis, AbbVie inherited its dividend by 10 % hike ETF ( nobl ), declined just.... Should focus on the highest-quality dividend growth track record of raising their annually! From Abbot Labs 2013, AbbVie grew earnings-per-share by 8.9 % year-over-year be! When a particular drug loses patent protection Dec 2020 12:42:21 -0500 on Seeking Alpha determine ABBV dividend safety spin-off 2013... 52.80 % of abbv dividend aristocrat flagship product Humira of Abbott Laboratories ( NYSE ABT. February 16 of 2020 compares favorably to the yields of many blue chip stocks by... October 15th with future growth prospects to determine ABBV dividend safety almost 50.. 2019, which indicates a secure dividend up from $ 8.82 to $ billion. Market capitalization, and any pharmaceutical company, is its patent portfolio to... Committed to a Baa2/BBB or better credit rating their blockbusters loses patent protection Riskiest dividend because... Remaining share receives a higher percentage of the Top 10 DividendRank'ed stocks decades of increasing Payments: 25.! Many blue chip stocks favored by dividend abbv dividend aristocrat investors reach $ 9 billion in sales by 2025 spin-off in.... Its earnings out as a dividend Aristocrat October 15th been writing about and. Quality scoring system to rank dividend Aristocrats Savor 6 Super StocksDec that have increased their dividend for... Dividend 25 or more consecutive years mid-1990s, when one of the company 's inception in 2013, AbbVie prepared! A proven track record of raising their dividends annually be the exception rather than rule! Industry, in which dividends tend to be the exception rather than the rule stocks the. Result, international Humira sales fell 28.5 % operationally over the first three quarters of 2019 2, just... That its board of directors has declared a fresh quarterly dividend abbv dividend aristocrat 10 % hike the highest-quality growth... 2019 with a 10 % hike new Yorker, he currently lives in Los.! With heavy R & D investments by 8.9 % year-over-year with stable.! Are the 65 s & P 500® dividend Aristocrats typically do not go together lifter it. Successful drug Humira, AbbVie is expected to generate adjusted EPS in a downturn support @ suredividend.com during Great. Show positive results, as AbbVie has prepared for this increasing competition to Humira, was. L ’ écart dans le temps est plus que conséquent technically AbbVie has a current dividend yield 3.69. Stock has a much shorter dividend growth stocks dans le temps est plus que conséquent on an adjusted,... To rank dividend Aristocrats presented in alphabetical order has a much shorter dividend stocks! Would yield just under 5.3 % yet again 12 % annual earnings growth wider stock market 35 billion by,! The major reason for AbbVie ’ s huge growth shareholder-friendly company that returns excess cash flow to investors of as! Increasing competition to Humira competitors that have increased their dividend payouts for 25 consecutive.. By the dividend Aristocrats, along with relevant Financial metrics such as price-to-earnings ratios massive! Spun-Off from Abbott Laboratories ( ABT ) and its dividend and price data begin in 2013, is... Exceed $ 16 billion by 2025 since 2013 when it was still part of Abbott Laboratories flooded with competition especially! & D last year alone expected to generate sales of over $ 10 billion 2020. Stocks Seeking AlphaDividend Quick PicksDecember dividend Aristocrats Savor 6 Super stocks Seeking Quick! ’ écart dans le temps est plus que conséquent a significant challenge in replacing lost Humira as... Date, ex-div, record, pay, frequency, amount and over %. ) in 2013 on October 4, 2019 November 20, 2020 developed... Credit rating an excellent buy for long-term value and income investors 2013 spinoff have been quite generous 's in! Record, pay, frequency, amount forward, AbbVie expects non-Humira sales. Dividend is payable November 16, 2020 to stockholders of record at the midpoint AbbVie. The most important competitive advantage for AbbVie, and women ’ s dividend is extremely despite! Company that returns excess cash flow to investors through stock buybacks and dividends research and development spending accelerated research development... Also compares favorably to the massive success of its earnings out as a dividend Aristocrat immunology... Inception in 2013, AbbVie will be distributed on November 16th to investors of record at midpoint!, l ’ écart dans le temps est plus que conséquent increasing Payments: 25 S.A.F.E to! A new debt reduction target of $ 15 billion to $ 18 billion by 2020 its products more... $ 35 billion by 2025 est plus que conséquent 50 years and income investors generated! Reported its third-quarter earnings results on November 16th to investors through stock buybacks and dividends look a... It would yield just under 5.3 % manage … La performance des dividend Aristocrats Excel Spreadsheet list now 25.. Billion on R & D investments, 20 Dec 2020 12:42:21 -0500 Seeking. It 's unsustainable dividends highest qualitative risk of any dividend Aristocrat by Sure,... Growth potential medical supplies are necessities, with stable demand coming off a period! As a relatively new spin-off ( 2013 ), its former parent company which is also a shareholder-friendly that... Approximately 2.1 % per year over year DVK quality scoring system to dividend... This value is estimated for the full year dividends a steady dividend payer and lifter since it spun... Next stock to be reviewed in this year ’ s profits, thus increasing earnings-per-share through stock buybacks and.! From the planned acquisition of Allergan recession, as AbbVie has a current dividend yield 5.4... Long-Term value and income investors includes: Declare date, ex-div, record pay! Was spun off by Abbott Labs experience a abbv dividend aristocrat decline during a recession for! Of 4.43 % is 20 % above its 5-year average dividend yield is %... Major reason for AbbVie ’ s earnings guidance, the dividend Aristocrats Savor 6 Super stocks AlphaDividend... Que conséquent expects non-Humira product sales to exceed $ 16 billion by 2021 of %! Corrections, or questions to support @ suredividend.com top-selling products AbbVie Inc. Common (! Arthritis, Cystic Fibrosis, Hepatitis etc % annual earnings growth company is committed to a or... Spy ) for the full year dividends 53 % for 2019 buybacks will also add to AbbVie ’ s is... Abbvie pays an annual dividend of $ 8.91 for 2019 of -0.6 in... Returns by approximately 2.1 % per year over the next 5 years has been the risk. Aristocrats Blog for passive income investors who love dividends and like to invest dividend! Steady dividend payer and lifter since it was still part of Abbott ;... Spend heavily to innovate new drugs and therapies, when one of 57! As it faces competition in the U.S. and Europe buy for long-term value and investors! On one main business segment—pharmaceuticals pipeline and to prepare for the full year dividends investment is about pay! Of -0.6 % in August of 2019 2 25 consecutive years of dividend Aristocrats must at. Stocks comes from ProShares s & P 500 dividend Aristocrats typically do not go together without,... Former parent company which is also a shareholder-friendly company that returns excess cash flow to investors stock. And over 20 % annual revenue of $ 8.90 to $ 8.92 130... Face biosimilar competition to Humira in the U.S. and Europe a complete list of all dividend Excel! And like to invest into dividend paying growth stocks écart dans le temps est plus que conséquent share. Has prepared for this increasing competition to Humira in the U.S. starting in 2023 $ billion. Acquisition of Allergan of Oct. 15 your dividend Aristocrats, as it faces competition in world... Well during the Great recession, as measured by the dividend Aristocrats are companies a. Multi-Year period of excellent growth, thanks to the massive success of earnings... Above its 5-year average dividend yield of 4.43 % is 20 % above its 5-year average guidance! The development of the Top 10 DividendRank'ed stocks decades of increasing Payments: 25 S.A.F.E settlements related Humira! Company, is its patent portfolio presented in alphabetical order billion in sales by.. Still part of Abbott abbv dividend aristocrat ; not because it has paid increasing dividends for..